MeritValue

BIOADAPTIVES, INC.

BDPTdata completeness 88%10 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'dividendsPaid'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$19,7761$17,1762$28,5653$12,6694$18,2784
Net income−$1.05M5−$895,5706−$712,4667−$899,1618−$1.56M8
Operating cash flow−$158,6519−$227,25910−$223,77311−$249,51712−$516,02512
Capital expenditure———$013$18,00013
Free cash flow (derived)———−$249,51712−$534,02512
Total debt—————
Cash & equivalents$82,93614$82,93615$88,55716$261,88517$215,20517
Diluted shares50.8M252.6M6.0M8.2M10.1M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$2.11
your share of equity
Profit it earned you last year
−$1.55
Free cash flow it threw off
−$0.53
Debt you’d be carrying
—

10 shares is a claim on −$2.11 of net worth that earned you −$1.55 and generated −$0.53 of cash last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
−80% shares · 5y

Share count is down 80% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.5.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001640334-23-000532 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001640334-24-000602 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001640334-25-000660 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001640334-26-000718 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001640334-23-000532 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001640334-24-000602 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001640334-25-000660 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001640334-26-000718 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001640334-23-000532 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001640334-24-000602 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001640334-25-000660 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001640334-26-000718 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2024-12-31 · accession 0001640334-26-000718 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2021-12-31 · accession 0001640334-23-000532 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2022-12-31 · accession 0001640334-24-000602 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2023-12-31 · accession 0001640334-25-000660 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2024-12-31 · accession 0001640334-26-000718 (CashAndCashEquivalentsAtCarryingValue)